CompletedNCT01248052
A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers
Medication studyAges 21–65SingaporeBipolarity
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.
- Listed locations
- SingaporeSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateNovember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 25
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Singapore
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT01248052
- Official title
Show the full official title
Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY2979165 in Healthy Subjects
Get this study by email
Recruitment & locations
CompletedSingapore
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including LY2979165 and Placebo.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.
